Apologies if been posted .......
“Nearly 600 children admitted to U.S. hospitals with rare inflammatory illness linked to COVID-19”
MSB - EAP MSC with Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
The program is to treat approximate 50 children. I would think news very soon on results.
EXPANDED ACCESS PROTOCOL INITIATED FOR COMPASSIONATE USE OF REMESTEMCEL-L IN CHILDREN WITH MULTISYSTEM INFLAMMATORY SYNDROME ASSOCIATED WITH COVID-19
Melbourne, Australia; July 6, 2020; and New York, USA; July 5, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that an expanded access protocol (EAP) has been initiated in the United States for compassionate use of its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L in the treatment of COVID-19 infected children with cardiovascular and other complications of multisystem inflammatory syndrome (MIS-C). Patients aged between two months and 17 years may receive one or two doses of remestemcel-L within five days of referral under the EAP.
The protocol was filed with the United States Food and Drug Administration (FDA) and provides physicians with access to remestemcel-L for an intermediate-size patient population1 under Mesoblast’s existing Investigational New Drug (IND) application. According to the FDA, expanded access is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.
MIS-C is a life-threatening complication of COVID-19 in otherwise healthy children and adolescents that includes massive simultaneous inflammation of multiple critical organs and their vasculature. In approximately 50% of cases this inflammation is associated with significant cardiovascular complications that directly involve heart muscle and may result in decreased cardiac function. In addition, the virus can result in dilation of coronary arteries with unknown future consequences. Recent articles from Europe and the United States have described this disease in detail.2-5
Mesoblast Chief Medical Officer Dr Fred Grossman said: “The extensive body of safety and efficacy data generated to date using remestemcel-L in children with graft versus host disease suggest that our cellular therapy could provide a clinically important therapeutic benefit in MIS-C patients, especially if the heart is involved as a target organ for inflammation. Use of remestemcel-L in children with COVID-19 builds on and extends the potential application of this cell therapy in COVID-19 cytokine storm beyond the most severe adults with acute respiratory distress syndrome.”
PERSPECTIVE
David Cennimo, MD
David Cennimo
This is an interesting advance in the potential treatment of MIS-C, further targeting the immune reaction to recent infection as the cause of the organ dysfunction. Multiple reports have been recently published highlighting the heterogeneous and sometimes very severe presentation of MIS-C. In severe cases, especially in those with significant cardiac involvement, this syndrome has resulted in fatalities. The current treatment has centered on IV immune globulin and steroids, which it is hoped will modify the immune response and possible cytokine storm. Remestemcel-L would be another step in this immune modification. I would imagine that this treatment would be prioritized for the most severe cases.
David Cennimo, MD
Clinician and assistant professor of adult infectious diseases
Rutgers New Jersey Medical School
Newark, New Jersey
(20min delay)